【摘要】 为了探讨SP化疗方案(替吉奥+顺铂)一线治疗晚期胃癌临床疗效及毒副反应,对经病理学确诊的19例晚期胃癌患者采用SP方案化疗:替吉奥(S-1)按体表面积分别每次40(<1.25m2)、50(1.25～1.5m2)和60mg(>1.5m2)早晚各口服1次,d1～d21;顺铂30mg/m2静脉滴入d7～d8;5周为1个周期,直至肿瘤进展或不良反应无法耐受,每2个周期评价疗效及毒副反应。19例均可评价疗效,CR 1例,PR 7例,SD 6例,PD 5例,总有效率(RR)为42.1%(8/19),疾病控制率(DCR)为73.7%(14/19)。中位疾病进展时间(TTP)5.8个月,中位总生存期11.3个月,1年生存率为47.3%。毒副反应主要为血液学毒性及胃肠道反应,手足综合征发生率为21.0%。初步研究结果提示,SP方案治疗晚期胃癌有较高的疾病控制率,患者耐受性良好,生活质量高,是较理想的晚期胃癌一线治疗方案。更多还原

【Abstract】 The objective of this study was to observe the clinical effect and tolerance of S-1 combined with cisplatin as first-line chemotherapy treatment of patients with advanced gastric cancer.Nineteen patients with advanced gastric cancer were enrolled in this study and received chemotherapy of SP regimen:different dose S-1(40,50 and 60 mg based on body surface area) was given orally d1-d21,twice a day,cisplatin(30 mg/m2) by intravenous infusion from d7-d8,repeated every 5 weeks and continued until disease progression or intolerable toxicity.The efficacy and adverse events were evaluated after two cycles.Nineteen patients were valuable for efficacy.One case achieved CR,7 cases achieved PR,6 cases had SD,and 5 cases experienced PD.The overall response rate(CR+PR) was 42.1%(8/19),and disease control rate was 73.7%(14/19).The median TTP was 5.8 months,median overall survival was 11.3 months,and 1-year survival rate was 47.3%.Main side effects included hematology toxicity,gastrointestinal response,with low hand-foot syndrome(21.0%).In conclusion,the regimen of S-1 plus combined cisplatin have shown effective and well-tolerated as first-line chemotherapy for advanced gastric cancer with high quality of life and disease control rate.更多还原